Loyal Valley Capital is a thematic, research-driven private equity firm.
Loyal Valley Capital (LVC) is a thematic, research-driven private equity firm with strong entrepreneurial culture that invests in middle market companies positioned to benefit from the secular industry transformations in China. With over US$1.6 billion of assets under management, LVC mainly focuses on the following segments: Consumer (TMT, Internet, and Education), Healthcare, and Advanced Manufacturing. Our investment process is characterized by in-depth top-down and bottom-up fundamental research to uncover secular themes and utilize extensive industry mapping to deploy capital in a high conviction and disciplined approach. We pride ourselves as a trusted influential shareholder relentlessly focused on active value creation and accelerating growth via strategic initiatives through our extensive network of business leaders in China. LVC manages capital on behalf of international institutional investors such as sovereign wealth funds, funds of funds, private banks, and family offices, as well as elite entrepreneurs and founders of China’s Fortune 500 enterprises.LVC was founded in 2015 by Andy Lin, an experienced investor and accomplished entrepreneur. He is the founder of China Universal Asset Management (“CUAM”), one of China’s largest equity investor and asset manager with over US$100B in AUM, known for its industry leading research and award-winning investment records.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Mar 14, 2022
Medilink Therapeutics
|
Series B | $70M | Biotechnology | — |
Mar 1, 2021
Medilink Therapeutics
|
Series A | $50M | Biotechnology | Yes |
Apr 29, 2020
Mabwell Biotech
|
Series A | $278.50M | Biopharma | — |
Oct 25, 2018
ByteDance
|
Series E | $3B | Content | — |
Feb 27, 2018
GeneCast Biotechnology
|
Series C | $33M | Biotechnology | Yes |